Related Experiment Videos
Plasma transforming growth factor-beta1 levels in patients with erectile dysfunction
Ji-Kan Ryu1, Sun U Song, Hyung-Ki Choi
1Department of Urology, Inha University School of Medicine, Incheon, Korea.
Asian Journal of Andrology
|November 17, 2004
Summary
Elevated plasma transforming growth factor-beta1 (TGF-beta1) levels are linked to erectile dysfunction (ED). This suggests TGF-beta1 may play a role in ED development, particularly in vasculogenic cases and those with vascular risk factors.
Area of Science:
- Urology
- Andrology
- Biochemistry
Background:
- Erectile dysfunction (ED) is a common condition with multifactorial causes.
- Transforming growth factor-beta1 (TGF-beta1) is implicated in fibrotic processes.
Purpose of the Study:
- To investigate plasma TGF-beta1 levels in patients with erectile dysfunction (ED).
- To compare TGF-beta1 levels across different etiologies of ED and in relation to vascular risk factors.
Main Methods:
- Plasma TGF-beta1 levels were measured using ELISA in 62 ED patients and 26 controls.
- ED causes were classified as psychogenic, neurogenic, or vasculogenic through comprehensive evaluation.
- Vascular risk factors including smoking and dyslipidemia were assessed.
Main Results:
- Plasma TGF-beta1 was significantly higher in ED patients compared to controls (6.7 vs. 4.0 ng/mL).
- Vasculogenic ED showed the highest TGF-beta1 levels, significantly elevated compared to psychogenic and neurogenic groups.
- Smoking and dyslipidemia were associated with significantly increased plasma TGF-beta1 levels.
Conclusions:
- Elevated plasma TGF-beta1 is associated with erectile dysfunction.
- Vascular risk factors contribute to increased TGF-beta1 levels in ED patients.
- TGF-beta1 may be a contributing factor to cavernous fibrosis and the development of ED.